.
.
..loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
the report was compiled by outside researchers who went into the fda�s own database of �serious adverse [medical-drug] events.�. would identify hospitals that are best positioned to treat strokes and establish protocols for emergency responders handling stroke patients..: "fremanezumab for the preventive treatment of chronic migraine.".